Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. CTMX
CTMX logo

CTMX News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

CTMX News

CytomX Therapeutics Named Among Top Small Cap Stocks by Wall Street

Feb 17 2026Yahoo Finance

Birkenstock, Insmed, and Other Major Stocks Decline in Thursday's Pre-Market Trading

Dec 18 2025Benzinga

Analysts Discuss the Evolving CytomX Narrative Following Recent Clinical Progress and Increased Price Target

Nov 22 2025Yahoo Finance

HC Wainwright & Co. Reaffirms Buy Rating for CytomX Therapeutics and Increases Price Target to $10

Nov 11 2025Benzinga

CytomX announces Q1 2026 data update for CX-2051 and achieves 100-patient enrollment milestone as Phase Ib study progresses.

Nov 07 2025SeekingAlpha

CytomX Therapeutics Stock: An In-Depth Look at Analyst Opinions (4 Ratings)

Oct 21 2025Benzinga

Barclays Keeps Overweight Rating on CytomX Therapeutics and Increases Price Target to $6

Oct 21 2025Benzinga

Cantor Fitzgerald Begins Coverage of CytomX Therapeutics with Overweight Rating and Sets Price Target at $6

Sep 22 2025Benzinga

CTMX Events

No data

No data

CTMX Monitor News

No data

No data

CTMX Earnings Analysis

No Data

No Data

People Also Watch